In FGD patients, SGPL1 variants lead to a pathological accumulation of S1P intermediates, including ceramides, which are known to be steroidogenesis inhibitors, thus overcoming S1P pro-secretive effects on cortisol production and therefore leading to AI [5]. Here, SGPL1 is linked to Aarskog-Scott syndrome, X-linked.